| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Proglutamine at concentrations of 0.3–10 mM quantitatively suppressed CCK-stimulated amylase production in an in vitro investigation, but proglutamine at values of 0–3 mM had no effect on basal amylase. liberated. The dose-response curve of amylase release vs CCK moves to the right as proglutamine concentration rises. Proglumide's inhibitory action is reversible. Proglumide is additionally selective for CCK and related peptides [2]. Proglumide dosage dramatically decreased [3H]-bust daily injection into HT29 cells with an IC50 of 6.5 mM in a dose-dependent manner. Proglumide has a dose-dependent effect in reducing the overall number of questions, with a dose-dependence of up to 70% on cells [3].
|
|---|---|
| ln Vivo |
Proglumide treatment (250–750 mg/kg; intraperitoneal injection; adult Sprague Dawley Project) dramatically reduces brain oxidation, cognitive dysfunction, and engineering activity [1].
|
| Animal Protocol |
Animal/Disease Models: Adult male Sprague Dawley rats (200) -250 g; 2 months old) induced status epilepticus (SE) [1]
Doses: 250 mg/kg, 500 mg/kg and 750 mg/kg administered Methods: intraperitoneal (ip) injection Experimental Results: Dose-dependent and significant increase in latency to seizures and SE. Significant and dose-dependent attenuated Li-PC (SE)-induced increases in thiobarbituric acid (TBARS) and catalase (CAT), attenuated Li-Pc-induced decreases in SOD, and attenuated GSH and Depletion of glutathione-S transferase (GST). Hippocampus and striatum. |
| References |
|
| Molecular Formula |
C18H25N2O4NA
|
|---|---|
| Molecular Weight |
356.3919
|
| Exact Mass |
356.171
|
| CAS # |
99247-33-3
|
| Related CAS # |
Proglumide;6620-60-6;Proglumide hemicalcium;85068-56-0
|
| PubChem CID |
23677833
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.538
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
25
|
| Complexity |
419
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UFMWGCINVOIJSO-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C18H26N2O4.Na/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14;/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22);/q;+1/p-1
|
| Chemical Name |
sodium;4-benzamido-5-(dipropylamino)-5-oxopentanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~280.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (280.59 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8059 mL | 14.0296 mL | 28.0591 mL | |
| 5 mM | 0.5612 mL | 2.8059 mL | 5.6118 mL | |
| 10 mM | 0.2806 mL | 1.4030 mL | 2.8059 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
